
    
      Within this clinical trial, the investigators will test the hypotheses that the
      administration of CTLs for prophylaxis against Ad, CMV and EBV in recipients of TCD-HPCT will
      be safe and well tolerated. Graded doses of Multi-Virus CTL will be administered to
      recipients of genotypically haploidentical or mismatched unrelated TCD grafts.
    
  